<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2012">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134974</url>
  </required_header>
  <id_info>
    <org_study_id>OPI-NYXRM-302 (MIRA-3)</org_study_id>
    <nct_id>NCT05134974</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)</brief_title>
  <acronym>MIRA-3</acronym>
  <official_title>Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuphire Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocuphire Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        -  To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced&#xD;
           mydriasis across multiple mydriatic agents with an emphasis on phenylephrine&#xD;
&#xD;
        -  To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after&#xD;
           worsening (with cycloplegic agents tropicamide and Paremyd)&#xD;
&#xD;
        -  To evaluate the safety of Nyxol&#xD;
&#xD;
        -  To evaluate any additional benefits of the reversal of pharmacologically-induced&#xD;
           mydriasis&#xD;
&#xD;
        -  To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, parallel arm, double-masked, placebo-controlled Phase 3 study in at least 330&#xD;
      randomized subjects, evaluating the safety and efficacy of Nyxol in subjects with&#xD;
      pharmacologically-induced mydriasis.&#xD;
&#xD;
      Following the successful completion of screening, each subject will be stratified by eye&#xD;
      color and then simultaneously be randomized to mydriatic agent (unmasked) and treatment&#xD;
      (masked). Treatment randomization will be 2:1, Nyxol or placebo (vehicle). Stratification by&#xD;
      iris color will be 1:1, light or dark rides. The mydriatic agent randomization will be 3:1:1&#xD;
      (2.5% phenylephrine, 1% tropicamide, and Paremyd).&#xD;
&#xD;
      At the treatment visit, subjects who have been randomized and stratified by iris color (1:1&#xD;
      [light/dark]) will receive one of three approved mydriatic agents approximately 1 hour prior&#xD;
      to receiving study treatment. Measurements will be measured before (-1 hour /baseline) and 60&#xD;
      minutes after (maximum/0 minutes) the mydriatic agent instillation in each eye (i.e. right&#xD;
      before the study treatment is administered), and at 30 minutes, 60 minutes, 90 minutes, 2&#xD;
      hours, 3 hours, 4 hours, and 6 hours after treatment dosing. Measurements will include pupil&#xD;
      diameter (PD), distance and near visual acuity (VA), accommodation, and redness in each eye.&#xD;
&#xD;
      Blood sampling for Nyxol PK measurements will be conducted in a subset of approximately 30&#xD;
      adult subjects at approximately two select study sites.&#xD;
&#xD;
      At the Follow-Up Visit, which is 1 day after Visit 1, measurements will again be recorded 24&#xD;
      hours after treatment dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects' Study Eyes with Pupil Diameter Returning to Baseline</measure>
    <time_frame>90 minutes</time_frame>
    <description>Percentage of subjects' study eyes returning to less than or equal to 0.2 mm from baseline pupil diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects' Study Eyes with Pupil Diameter Returning to Baseline</measure>
    <time_frame>30 minutes to 24 hours</time_frame>
    <description>Percentage of subjects' study eyes returning to less than or equal to 0.2 mm from baseline pupil diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil Diameter (Change from Max)</measure>
    <time_frame>30 minutes to 24 hours</time_frame>
    <description>Change (mm) from maximum pharmacologically-induced mydriatic pupil diameter (0 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Unchanged Accommodation from Baseline</measure>
    <time_frame>2 hours</time_frame>
    <description>Percentage of subjects with unchanged accommodation from baseline (-1 hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best-Corrected Distance Visual Acuity (BCDVA) Under Normal Photopic Lighting Versus Glare</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in best-corrected distance visual acuity (BCDVA) under normal photopic lighting versus glare</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Mydriasis</condition>
  <condition>Dilation</condition>
  <arm_group>
    <arm_group_label>Phentolamine Ophthalmic Solution 0.75%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentolamine Ophthalmic Solution Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution 0.75%</intervention_name>
    <description>0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist</description>
    <arm_group_label>Phentolamine Ophthalmic Solution 0.75%</arm_group_label>
    <other_name>Nyxol®</other_name>
    <other_name>Nyxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution Vehicle</intervention_name>
    <description>Phentolamine Ophthalmic Solution Vehicle</description>
    <arm_group_label>Phentolamine Ophthalmic Solution Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥ 12 years of age&#xD;
&#xD;
          2. Ability to comply with all protocol-mandated procedures independently and to attend&#xD;
             all scheduled office visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant ocular disease as deemed by the Investigator (eg, glaucoma,&#xD;
             corneal edema, uveitis, severe keratoconjunctivitis sicca) that might interfere with&#xD;
             the study&#xD;
&#xD;
          2. Unwilling or unable to discontinue use of contact lenses at screening until study&#xD;
             completion&#xD;
&#xD;
          3. Unwilling or unable to suspend use of topical medication at screening until study&#xD;
             completion&#xD;
&#xD;
          4. Ocular trauma, ocular surgery, or non-refractive laser treatment within the 6 months&#xD;
             prior to screening&#xD;
&#xD;
          5. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of&#xD;
             any kind within 7 days of screening, with the exception of lid scrubs with OTC&#xD;
             products (eg, OCuSOFT® lid scrub, SteriLid®, baby shampoo, etc.)&#xD;
&#xD;
          6. Recent or current evidence of ocular infection or inflammation in either eye (such as&#xD;
             current evidence of clinically significant blepharitis, conjunctivitis, or keratitis).&#xD;
             Subjects must be symptom-free for at least 7 days prior to screening&#xD;
&#xD;
          7. Closed or very narrow-angle that in the Investigator's opinion is potentially&#xD;
             occludable if the subject's pupil is dilated&#xD;
&#xD;
          8. Prior participation in a study involving the use of Nyxol for the reversal of&#xD;
             mydriasis&#xD;
&#xD;
          9. Known hypersensitivity or contraindication to α- and/or β-adrenoceptor antagonists&#xD;
&#xD;
         10. Clinically significant systemic disease (eg, uncontrolled diabetes, myasthenia gravis,&#xD;
             cancer, hepatic, renal, endocrine, or cardiovascular disorders) that might interfere&#xD;
             with the study&#xD;
&#xD;
         11. Participation in any investigational study within 30 days prior to screening&#xD;
&#xD;
         12. Resting heart rate (HR) outside the normal range (50-110 beats per minute) at the&#xD;
             Screening Visit.&#xD;
&#xD;
         13. Hypertension with resting diastolic blood pressure (BP)&gt;105 mmHg or systolic BP &gt; 160&#xD;
             mmHg at the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roselyn Judd, BS</last_name>
    <phone>586-212-0237</phone>
    <email>roselyn.judd@oculoscr.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Drey Coleman</last_name>
    <phone>8134041993</phone>
    <email>dcoleman@ocuphire.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Site 11</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 10</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 9</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 8</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 6</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 1</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 5</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 2</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 4</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 7</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 3</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nyxol</keyword>
  <keyword>Pharmacologically Induced Mydriasis</keyword>
  <keyword>Dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriasis</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

